keyword
MENU ▼
Read by QxMD icon Read
search

Aripiprazole

keyword
https://www.readbyqxmd.com/read/28342578/efficacy-and-safety-of-aripiprazole-lauroxil-in-schizophrenic-patients-presenting-with-severe-psychotic-symptoms-during-an-acute-exacerbation
#1
Steven G Potkin, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Bernard Silverman, Srdjan Stankovic, Elliot Ehrich
Aripiprazole lauroxil (AL), a new long-acting injectable antipsychotic, demonstrated safety and efficacy in treating acute exacerbation symptoms of schizophrenia in a 12-week placebo-controlled trial of two doses of AL (441mg and 882mg) administered every 4weeks. We performed a post hoc analysis of this trial to evaluate the efficacy of AL in the subgroup of patients with severe psychotic symptoms, defined as those with baseline Positive and Negative Syndrome Scale (PANSS) Total score above the median score of 92 (n=309)...
March 22, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28341090/transient-isolated-lower-bulbar-palsy-with-elevated-serum-anti-gm1-and-anti-gd1b-antibodies-during-aripiprazole-treatment
#2
Tae Hwan Han, Do Yeon Kim, Dong Woo Park, Jin-Hwa Moon
BACKGROUND: Transient bulbar palsy without involvement of the facial or extraocular muscles is a rare presentation. It is considered a form of cranial polyneuropathy, a variant of Guillain-Barré syndrome that is related to the autoimmune mechanisms induced by preceding infections or vaccinations. However, drug-induced cranial polyneuropathy has not previously been reported. We describe a boy with isolated bulbar palsy and positive serum antiganglioside antibodies during aripiprazole treatment...
January 2017: Pediatric Neurology
https://www.readbyqxmd.com/read/28335658/dopamine-antagonists-for-treatment-resistance-in-autism-spectrum-disorders-review-and-focus-on-bdnf-stimulators-loxapine-and-amitriptyline
#3
Jessica A Hellings, L Eugene Arnold, Joan Han
Drug development is urgently needed for individuals with autism spectrum disorders (ASD) and psychiatric comorbidity, which often presents as aggression and self-injury. At the same time, most psychiatric medications are drugs that have been repurposed following clinical observations of efficacy for a new treatment purpose. Areas Covered: This review aims to provide an overview of dopamine antagonists, including classical and atypical, as well as unconventional antipsychotics in ASD, since they are a mainstay of treatment for such problems...
March 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28334528/why-prodrugs-and-propesticides-succeed
#4
John E Casida
What are the advantages of bioactivation in optimizing drugs and pesticides? Why are there so many prodrugs and propesticides? These questions are examined here by considering compounds selected on the basis of economic value or market success. The 100 major drugs and 90 major pesticides are divided into ones acting directly and those definitely or possibly requiring bioactivation. Established or candidate prodrugs accounted for 19% of the total drug sales with corresponding values of 20, 37 and 17% for proinsecticides, proherbicides and profungicides...
March 23, 2017: Chemical Research in Toxicology
https://www.readbyqxmd.com/read/28334444/the-partial-dopamine-d2-receptor-agonist-aripiprazole-is-associated-with-weight-gain-in-adolescent-anorexia-nervosa
#5
Guido K W Frank, Megan E Shott, Jennifer O Hagman, Marissa A Schiel, Marisa C DeGuzman, Brogan Rossi
OBJECTIVE: Finding medication to support treatment of anorexia nervosa has been difficult. Neuroscience-based approaches may help in this effort. Recent brain imaging studies in adults and adolescents with anorexia nervosa suggest that dopamine-related reward circuits are hypersensitive and could provide a treatment target. METHODS: Here, we present a retrospective chart review of 106 adolescents with anorexia nervosa some of whom were treated with the dopamine D2 receptor partial agonist aripiprazole during treatment in a specialized eating disorder program...
March 23, 2017: International Journal of Eating Disorders
https://www.readbyqxmd.com/read/28333668/development-of-extemporaneously-compounded-aripiprazole-oral-suspensions-for-use-in-children
#6
Lance A Pramann, Lawrence W Davidow, Leon van Haandel, Ryan S Funk
The purpose of this study was to develop extemporaneously compounded oral liquid formulations of aripiprazole for use in pediatric patients and those patients unable to swallow the solid oral dosage forms. Aripiprazole tablets(30 mg) were ground to a fine powder and suspended at a concentration of 1.0 mg/mL in either a 1:1 blend of Ora-Plus and Ora-Sweet, or 1% methylcellulose and Simple Syrup NF. Five amber, plastic liquid prescription bottles of each formulation were stored at 4°C, and aripiprazole content was measured by ultra-performance liquid chromatography time-of-flight mass spectrometry at 0, 14, 32, 67, and 91 days...
May 2016: International Journal of Pharmaceutical Compounding
https://www.readbyqxmd.com/read/28333365/clozapine-combined-with-different-antipsychotic-drugs-for-treatment-resistant-schizophrenia
#7
REVIEW
Sarah Barber, Uwaila Olotu, Martina Corsi, Andrea Cipriani
BACKGROUND: Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels. For these people, a number of treatment strategies have emerged, including the prescription of a second anti-psychotic drug in combination with clozapine. OBJECTIVES: To determine the clinical effects of various clozapine combination strategies with antipsychotic drugs in people with treatment-resistant schizophrenia both in terms of efficacy and tolerability...
March 23, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28331332/clinical-role-of-brexpiprazole-in-depression-and-schizophrenia
#8
REVIEW
Nishant B Parikh, Diana M Robinson, Anita H Clayton
Brexpiprazole, a serotonin-dopamine activity modulator, is the second D2 partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D2 receptor and higher potency at 5-HT2A, 5-HT1A, and α1B receptors, the pharmacological properties of brexpiprazole suggest a more tolerable side effect profile with regard to akathisia, extrapyramidal dysfunction, and sedation. While no head-to-head data are currently available, double-blind placebo-controlled studies show favorable results, with the number needed to treat (NNT) vs placebo of 6-15 for response in acute schizophrenia treatment and 4 for maintenance...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28317392/pharmacotherapy-of-major-depression-in-late-life-what-is-the-role-of-new-agents
#9
Kinjal Patel, Petal S Abdool, Tarek K Rajji, Benoit H Mulsant
Evidence on the pharmacotherapy of late-life major depressive disorder (LLD) is scant. Most of the recommendations in existing clinical guidelines are based on expert opinions, extrapolations from data obtained in younger patients, or theoretical considerations. AREAS COVERED This article summarizes the recommendations from existing clinical guidelines and recent reviews on the treatment of LLD. Next, it discusses the potential role of newer antidepressants -vilazodone, levomilnacipran, and vortioxetine- based on a systematic search of the literature published during the past five years...
March 20, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28296430/successful-use-of-sertindole-for-severe-behavioral-dyscontrol-in-a-pediatric-case-of-syndromic-autism-spectrum-disorder
#10
Ahmed Naguy
Autism spectrum disorder (ASD) is commonly associated with a host of challenging behaviors. Pharmacotherapy is indicated if psychosocial and educational interventions fail. Atypical antipsychotics have the strongest evidence base so far, with both risperidone and aripiprazole being FDA approved. Unfortunately, their use is fraught with metabolic and neurohormonal side effects. In this study, the author is reporting on a case of syndromic ASD/moderate intellectual disability with severe behavioral component that failed multiple psychotropic trials and ultimately responded dramatically to sertindole...
March 15, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/28291301/-acute-dystonia-due-to-aripiprazole-use-in-two-children-with-autism-spectrum-disorder-in-the-first-five-years-of-life
#11
Mustafa Küçükköse, Bürge Kabukçu Başay
Autism spectrum disorders (ASD) are neuropsychiatric disorders characterized by impairment in social interactions, in verbal and non-verbal communication, and restricted and stereotyped patterns of interest and behavior within the first 3 years of life. Pharmacologic interventions may be needed for the treatment of temper tantrums, aggression, hyperactivity, and stereotypes in children with ASD. The approval of aripiprazole by the United States Food and Drug Administration (USFDA) for the treatment of temper tantrums in children and adolescents with ASD has gained increased interest for the use in these patients...
2017: Türk Psikiyatri Dergisi, Turkish Journal of Psychiatry
https://www.readbyqxmd.com/read/28290080/a-retrospective-cohort-study-of-acute-kidney-injury-risk-associated-with-antipsychotics
#12
Yawen Jiang, Jeffrey S McCombs, Susie H Park
BACKGROUND: A recent large database analysis raised concerns of potential acute kidney injury (AKI) risk associated with antipsychotics. However, whether individual atypical and typical antipsychotics are associated with differential AKI risks has not been investigated. OBJECTIVE: The current study compared the risks of AKI and known causes of AKI associated with a broad range of atypical and typical antipsychotics. METHOD: This retrospective cohort analysis used January 2007-June 2013 US nationwide Humana claims data to define episodes of antipsychotic drug therapy for patients with schizophrenia and bipolar disorder...
March 13, 2017: CNS Drugs
https://www.readbyqxmd.com/read/28272307/blood-biomarkers-predict-the-cognitive-effects-of-aripiprazole-in-patients-with-acute-schizophrenia
#13
Hikaru Hori, Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Ryohei Igata, Yuki Konishi, Hiroki Beppu, Hirotaka Tominaga
Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia. Therefore, in the present study, we evaluated biological markers, clinical data, and psychiatric symptoms in order to identify factors that influence cognitive function in patients with schizophrenia undergoing aripiprazole treatment. We evaluated cognitive function in 51 patients with schizophrenia using Brief Assessment of Cognition in Schizophrenia (BACS), as well as background information, psychiatric symptoms, plasma catecholamine metabolites-homovanillic acid (HVA), 3-methoxy-4-hydroxyphenylglycol (MHPG)-, and serum brain-derived neurotrophic factor (BDNF)...
March 6, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28264635/lurasidone-compared-to-other-atypical-antipsychotic-monotherapies-for-bipolar-depression-a-systematic-review-and-network-meta-analysis
#14
Michael Ostacher, Daisy Ng-Mak, Pankaj Patel, Dionysios Ntais, Max Schlueter, Antony Loebel
OBJECTIVES: To assess the efficacy and tolerability of lurasidone versus other atypical antipsychotic monotherapy agents in patients with bipolar depression, using a Bayesian network meta-analysis. METHODS: Fourteen randomised clinical trials (6221 patients) of lurasidone, quetiapine (extended release and immediate release), aripiprazole, olanzapine, and ziprasidone for bipolar depression were included. Efficacy assessments included change in the Montgomery-Åsberg Depression Rating Scale (MADRS), rates of response (≥50% improvement in MADRS) and remission (MADRS ≤12 at study endpoint), and change in the Clinical Global Impressions-Bipolar Disorder-Severity (CGI-BP-S) scale...
March 7, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28262171/partial-regimen-replacement-with-aripiprazole-reduces-serum-prolactin-in-patients-with-a-long-history-of-schizophrenia-a-case-series
#15
Keiko Naono-Nagatomo, Hisao Naono, Hiroshi Abe, Ryuichiro Takeda, Hideki Funahashi, Daisuke Uchimura, Yasushi Ishida
AIM: Aripiprazole (ARP) is a popular antipsychotic drug that has demonstrated ameliorative effects on hyperprolactinemia. However, no study to date has studied the utility of ARP in patients with a long history of schizophrenia and antipsychotic treatment. We therefore examined the effect of partial antipsychotic regimen replacement with ARP on hyperprolactinemia induced by chronic antipsychotic use in patients with schizophrenia. METHODS: Sixteen patients with a schizophrenia diagnosis (F2) based on the International Classification of Diseases (version 10) were recruited...
February 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28255444/switching-to-aripiprazole-for-the-treatment-of-residual-mutism-resulted-in-distinct-clinical-courses-in-two-catatonic-schizophrenia-cases
#16
Katsumasa Muneoka, Nobuhisa Kanahara, Shou Kimura
OBJECTIVES: The efficacy of a partial agonist for the dopamine D2 receptor, aripiprazole, for catatonia in schizophrenia has been reported. METHODS: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. RESULTS: In the first case, mutism was successfully treated when the patient was switched from olanzapine to aripiprazole. In contract, switching to aripiprazole from risperidone aggravated auditory hallucinations in the second case...
2017: SAGE open medical case reports
https://www.readbyqxmd.com/read/28255435/the-effect-of-long-acting-paliperidone-palmitate-once-monthly-on-negative-and-depressive-symptoms-in-patients-with-schizophrenia-switched-from-previous-unsuccessful-treatment-with-oral-aripiprazole
#17
Andreas Schreiner, Paul Bergmans, Pierre Cherubin, Ludger Hargarter
BACKGROUND: The negative symptoms of schizophrenia are generally harder to recognize, more difficult to treat than positive symptoms, and have a significant impact on patient functioning and overall outcomes. Treatment with aripiprazole may be associated with benefits on negative symptoms and functioning given its partial agonism to the dopamine D2 receptor. The aim of this subanalysis was to explore the impact of flexibly dosed, long-acting paliperidone palmitate once monthly (PP1M) on negative and depressive symptoms, disorganized thoughts, anxiety, extrapyramidal symptoms, and patient functioning in nonacute adult patients with schizophrenia previously unsuccessfully treated with oral aripiprazole monotherapy...
February 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28252452/reduced-sexual-dysfunction-with-aripiprazole-once-monthly-versus-paliperidone-palmitate-results-from-qualify
#18
Steven G Potkin, Jean-Yves Loze, Carlos Forray, Ross A Baker, Christophe Sapin, Timothy Peters-Strickland, Maud Beillat, Anna-Greta Nylander, Peter Hertel, Henrik Steen Andersen, Anna Eramo, Karina Hansen, Dieter Naber
Sexual dysfunction, a common side effect of antipsychotic medications, may be partly caused by dopamine antagonism and elevation of prolactin. In QUALIFY, a randomized study, aripiprazole once-monthly 400 mg (AOM 400), a dopamine D2 receptor partial agonist, showed noninferiority and subsequent superiority versus paliperidone palmitate (PP), a dopamine D2 receptor antagonist, on the Heinrichs-Carpenter Quality-of-Life Scale (QLS) in patients with schizophrenia aged 18-60 years. Sexual dysfunction (Arizona Sexual Experience Scale) and serum prolactin levels were also assessed...
March 1, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28235557/multidisciplinary-consensus-on-the-therapeutic-recommendations-for-iatrogenic-hyperprolactinemia-secondary-to-antipsychotics
#19
REVIEW
Ángel-Luis Montejo, Celso Arango, Miquel Bernardo, José-Luis Carrasco, Benidicto Crespo-Facorro, Juan-Jesús Cruz, Javier Del Pino-Montes, Miguel-Alfonso García-Escudero, Clemente García-Rizo, Ana González-Pinto, Ana-Isabel Hernández, Manuel Martín-Carrasco, Fermín Mayoral-Cleries, Jaqueline Mayoral-van Son, María-Teresa Mories, Isabella Pachiarotti, Jesús Pérez, Salvador Ros, Eduard Vieta
Hyperprolactinemia is an underappreciated/unknown adverse effects of antipyschotics. The consequences of hyperprolactinemia compromise therapeutic adherence and can be serious. We present the consensus recommendations made by a group of experts regarding the management of antipsychotic-induced hyperprolactinemia. The current consensus was developed in 3 phases: 1, review of the scientific literature; 2, subsequent round table discussion to attempt to reach a consensus among the experts; and 3, review by all of the authors of the final conclusions until reaching a complete consensus...
February 21, 2017: Frontiers in Neuroendocrinology
https://www.readbyqxmd.com/read/28225385/two-cases-of-oral-somatic-delusions-ameliorated-with-brain-perfusion-asymmetry-a-case-report
#20
Yojiro Umezaki, Akihito Uezato, Akira Toriihara, Toru Nishikawa, Akira Toyofuku
BACKGROUND: Oral cenesthopathy is the complaint of abnormal oral sensation where no underlying organic cause can be identified. It is also called oral dysesthesia or oral somatic delusion and classified as delusional disorder, somatic type. The patients with oral cenesthopathy show right > left asymmetric regional cerebral blood flow (rCBF) in the broad brain region. However, the studies scrutinizing the rCBF change before and after the successful treatment are still a few so far. CASE: We present 2 cases of oral cenesthopathy, who responded well to aripiprazole...
March 2017: Clinical Neuropharmacology
keyword
keyword
4828
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"